https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-approval-for-u-k-clinical-trial-investigating-reolysinr-in-combination-with-gemcitabine/ 2007-01-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-approval-for-u-k-clinical-trial-investigating-reolysinr-in-combination-with-docetaxel/ 2007-01-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-research-collaborators-to-present-reovirus-data-at-society-of-academic-research-surgery-conference/ 2007-01-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-18th-u-s-patent/ 2007-01-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-appointment-of-vice-president-intellectual-property/ 2007-01-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-public-offering/ 2007-02-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-pricing-of-previously-announced-public-offering/ 2007-02-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-closing-of-public-share-offering/ 2007-02-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-reports-highlights-and-financial-results-for-2006/ 2007-03-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-19th-u-s-patent/ 2007-03-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-reovirus-gemcitabine-combination-research-at-aacr-annual-meeting/ 2007-03-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-invest-northwest-ceo-and-investor-conference/ 2007-03-15T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-research-collaborators-to-present-combination-reovirus-and-cisplatin-treatment-results-at-oncolytic-virus-conference/ 2007-03-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-research-collaborators-to-present-reovirus-treatment-in-melanoma-animal-models-at-international-oncolytic-virus-conference/ 2007-03-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-research-collaborators-present-combination-reovirus-and-cyclophosphamide-treatment-results-at-international-oncolytic-virus-conference/ 2007-03-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-closing-of-over-allotment-option/ 2007-03-21T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-20th-u-s-patent/ 2007-04-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-proceeds-to-initiate-u-s-phase-ii-sarcoma-clinical-trial/ 2007-04-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-research-collaborators-demonstrate-reovirus-gemcitabine-combination-has-synergistic-effect-against-human-colon-cancer-cell-lines/ 2007-04-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2007-first-quarter-results/ 2007-04-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-successfully-completes-initial-scale-up-of-manufacturing-process-for-reolysinr/ 2007-04-30T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-details-of-2007-annual-shareholder-meeting/ 2007-05-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/u-s-nci-files-for-phase-2-systemic-melanoma-clinical-trial-with-reolysinr/ 2007-05-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-21th-u-s-patent/ 2007-05-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-starts-patient-enrolment-in-u-k-combination-reolysinr-paclitaxel-and-carboplatin-trial/ 2007-05-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-s-research-collaborators-to-present-reolysinr-clinical-trial-data-at-asco-conference/ 2007-06-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-positive-clinical-data-from-u-s-phase-i-reolysinr-trial/ 2007-06-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-starts-patient-enrolment-in-u-k-combination-reolysinr-gemcitabine-trial/ 2007-06-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-commences-patient-enrolment-in-u-s-phase-ii-sarcoma-clinical-trial/ 2007-06-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-6th-canadian-patent/ 2007-06-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-beginnt-mit-der-patientenaufnahme-in-die-britische-kombinationsstudie-zu-reolysinr-mit-docetaxel/ 2007-07-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-starts-patient-enrolment-in-u-k-combination-reolysinr-docetaxel-trial/ 2007-07-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2007-second-quarter-results/ 2007-07-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-22nd-u-s-patent/ 2007-08-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-23rd-u-s-patent/ 2007-09-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/reovirus-infection-of-melanoma-cells-generates-anti-tumour-immunity/ 2007-09-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-to-present-at-8th-peace-conference-on-protein-expression-in-animal-cells/ 2007-09-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-reports-positive-interim-results-of-u-k-phase-ia-ib-combination-reolysinr-and-radiation-clinical-trial/ 2007-09-28T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-biopartnering-europe-2/ 2007-10-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-bio-investorforum-2007/ 2007-10-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-approval-for-u-k-clinical-trial-investigating-reolysinr-in-combination-with-cyclophosphamide/ 2007-10-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-positive-interim-results-of-u-k-phase-ia-ib-combination-reolysinr-and-radiation-clinical-trial/ 2007-10-24T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2007-third-quarter-results/ 2007-10-30T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-acumen-biofin-rodman-renshaw-9th-annual-healthcare-conference/ 2007-11-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-bio-europe-2007/ 2007-11-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-toronto-cfa-society/ 2007-11-15T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-24th-u-s-patent/ 2007-11-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-to-present-at-annual-vaccine-production-conference/ 2007-11-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-25th-u-s-patent/ 2007-12-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-completes-patient-enrolment-in-u-k-phase-ia-ib-combination-reolysinr-radiation-clinical-trial/ 2007-12-21T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-filing-of-phase-1-2-clinical-trial-with-reolysinr/ 2008-01-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-publication-of-research-on-combination-reovirus-and-cyclophosphamide-treatment/ 2008-01-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-7th-canadian-patent/ 2008-01-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-8th-canadian-patent/ 2008-01-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-proceeds-to-full-enrolment-in-u-s-phase-ii-sarcoma-clinical-trial/ 2008-01-31T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-publication-of-research-on-combination-reovirus-and-radiation-therapy/ 2008-02-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-bio-ceo-investor-conference/ 2008-02-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-oncology-biologics-development-primer/ 2008-02-21T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-reports-highlights-and-financial-results-for-2007/ 2008-03-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-biosquare-2008/ 2008-03-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-reovirus-research-at-aacr-annual-meeting/ 2008-03-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-publication-of-research-on-immune-response-to-reolysinr-during-a-phase-i-clinical-trial/ 2008-03-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-26th-u-s-patent/ 2008-03-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-details-of-2008-annual-shareholder-meeting/ 2008-05-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-starts-patient-enrolment-in-u-k-combination-reolysinr-cyclophosphamide-trial/ 2008-05-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-u-k-phase-ii-clinical-trial-investigating-reolysinr-in-combination-with-paclitaxel-and-carboplatin/ 2008-05-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-phase-ii-sarcoma-trial-results-at-asco-annual-meeting/ 2008-05-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-27th-u-s-patent/ 2008-05-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-transfers-40-litre-cgmp-manufacturing-process-for-reolysinr/ 2008-05-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-9th-canadian-patent/ 2008-05-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-reovirus-research-at-asgt-meeting/ 2008-05-30T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-positive-phase-ii-sarcoma-trial-results-at-asco-annual-meeting/ 2008-06-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-starts-patient-enrolment-in-u-k-phase-ii-clinical-trial-investigating-reolysinr-in-combination-with-paclitaxel-and-carboplatin/ 2008-06-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-start-of-enrolment-in-phase-1-2-ovarian-cancer-clinical-trial-with-reolysinr/ 2008-06-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-to-present-at-bio-2008-international-convention/ 2008-06-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-u-s-phase-2-clinical-trial-investigating-reolysinr-in-combination-with-paclitaxel-and-carboplatin/ 2008-06-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-treats-200th-cancer-patient-in-clinical-studies-with-reolysinr/ 2008-07-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/r-e-p-e-a-t-oncolytics-biotech-inc-announces-u-s-phase-2-combination-clinical-trial-for-non-small-cell-lung-cancer-patients-with-k-ras-or-egfr-activated-tumours/ 2008-09-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-u-s-phase-2-combination-clinical-trial-for-non-small-cell-lung-cancer-patients-with-k-ras-or-egfr-activated-tumours/ 2008-09-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-starts-patient-enrolment-in-u-s-phase-2-clinical-trial-investigating-reolysinr-in-combination-with-paclitaxel-and-carboplatin/ 2008-09-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-reolysinr-clinical-trial/ 2008-09-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-28th-u-s-patent/ 2008-09-30T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-maxim-group-growth-conference/ 2008-10-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-29th-u-s-patent/ 2008-10-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-completes-initial-scale-up-of-manufacturing-process-for-reolysinr-to-commercial-scale/ 2008-10-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-biopartnering-europe/ 2008-10-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-bio-investor-forum-2008/ 2008-10-21T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-preclinical-combination-reolysinr-and-cisplatin-research-at-eortc-nci-aacr-annual-meeting/ 2008-10-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-combination-reolysinr-and-paclitaxel-carboplatin-results-at-isbtc-annual-meeting/ 2008-10-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-combination-reolysinr-and-docetaxel-results-at-isbtc-annual-meeting/ 2008-10-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-reovirus-and-melanoma-research-at-eortc-nci-aacr-symposium/ 2008-10-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-clinical-update-conference-call/ 2008-11-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-positive-phase-i-ii-combination-reolysinr-and-paclitaxel-carboplatin-results-at-isbtc-annual-meeting/ 2008-11-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-positive-combination-reolysinr-and-docetaxel-results-at-isbtc-annual-meeting/ 2008-11-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2008-third-quarter-results/ 2008-11-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-decision-to-pursue-phase-ii-iii-pivotal-clinical-trial/ 2008-11-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-u-s-phase-ii-sarcoma-clinical-trial-conference-call/ 2008-11-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-rodman-renshaw-10th-annual-healthcare-conference/ 2008-11-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-investigators-present-interim-u-s-reolysinr-phase-ii-sarcoma-trial-data/ 2008-11-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-reolysinr-research-at-ctos-annual-meeting/ 2008-11-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-30th-u-s-patent/ 2008-11-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-s-reolysinr-exceeds-primary-statistical-endpoint-in-u-s-phase-2-sarcoma-study/ 2008-12-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-amends-terms-of-previously-issued-broker-warrants/ 2008-12-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-completes-patient-enrolment-in-two-u-k-reolysinr-combination-therapy-clinical-trials/ 2008-12-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-appoints-dr-matt-coffey-as-chief-operating-officer/ 2008-12-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-31st-u-s-patent/ 2009-01-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-start-of-patient-enrolment-in-translational-clinical-trial-investigating-reolysinr-in-patients-with-metastatic-colorectal-cancer/ 2009-01-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/cancer-therapy-research-center-at-the-university-of-texas-health-science-center-and-oncolytics-biotechr-inc-announce-multi-trial-clinical-research-collaboration/ 2009-02-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotechr-inc-to-present-at-biopartnering-north-america-2/ 2009-02-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-2009-first-quarter-results/ 2009-05-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolyticsr-biotech-inc-completes-patient-enrolment-in-u-s-phase-2-sarcoma-study/ 2009-05-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-s-research-collaborators-to-present-data-on-reolysinr-clinical-trials-at-asco-conference/ 2009-05-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-collaborators-present-positive-phase-ii-sarcoma-trial-results-at-asco-annual-meeting/ 2009-06-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-completes-patient-enrolment-in-u-k-combination-reolysinr-and-paclitaxel-carboplatin-head-and-neck-cancer-trial/ 2009-07-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-research-collaborators-present-glioma-reovirus-research-at-asv-annual-meeting/ 2009-07-15T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-publication-of-research-on-synergistic-activity-of-reovirus-and-chemotherapy-in-nsclc/ 2009-07-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-completes-lyophilization-process-for-reolysinr/ 2009-07-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-successfully-completes-100-litre-cgmp-production-of-reolysinr/ 2009-07-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-2009-second-quarter-results/ 2009-07-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-issuance-of-32nd-u-s-patent/ 2009-09-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-rodman-renshaw-11th-annual-healthcare-conference/ 2009-09-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-r-accelerates-warrant-expiry-date/ 2009-09-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-reovirus-and-cisplatin-research-supports-u-s-phase-2-metastatic-melanoma-trial/ 2009-09-24T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-start-of-enrolment-in-u-s-phase-2-melanoma-cancer-clinical-trial/ 2009-09-24T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-phase-3-update-conference-call/ 2009-10-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-accelerates-warrant-expiry-date/ 2009-10-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-reaches-special-protocol-assessment-agreement-with-the-fda-on-design-of-phase-3-trial-for-reolysinr-in-head-and-neck-cancers/ 2009-10-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotechr-inc-to-present-at-biopartnering-europe/ 2009-10-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-investment-in-private-biotechnology-company/ 2009-10-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-bio-investor-forum-2009/ 2009-10-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-results-of-first-warrant-expiry-date-acceleration-program/ 2009-10-26T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolyticsr-biotech-inc-announces-issuance-of-33rd-u-s-patent/ 2009-10-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-collaborators-to-present-phase-ii-sarcoma-trial-results-at-ctos-annual-meeting/ 2009-10-30T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotechr-inc-to-present-at-bio-europe-2009/ 2009-11-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-results-of-second-warrant-expiry-date-acceleration-program/ 2009-11-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-2009-third-quarter-results/ 2009-11-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-collaborators-present-positive-phase-ii-sarcoma-trial-results-at-ctos-annual-meeting/ 2009-11-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-collaborators-to-present-updated-phase-i-ii-trial-results-in-advanced-solid-cancers-with-a-focus-on-the-head-and-neck-at-the-aacr-nci-eortc-meeting/ 2009-11-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-unit-offering/ 2009-11-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-collaborators-present-positive-phase-i-ii-trial-results-in-advanced-solid-cancers-with-a-focus-on-the-head-and-neck-at-the-aacr-nci-eortc-meeting/ 2009-11-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-terms-of-unit-offering/ 2009-11-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-closes-us12-75-million-unit-offering/ 2009-11-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-exercise-of-underwriters-over-allotment-option/ 2009-12-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-appoints-senior-vice-president-global-licensing-and-business-development/ 2009-12-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotechr-inc-to-present-at-biopartnering-north-america/ 2010-01-21T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotechr-inc-to-present-at-12th-annual-bio-ceo-investor-conference/ 2010-02-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-receives-approval-from-the-u-k-mhra-to-conduct-phase-3-trial-for-reolysinr-in-head-and-neck-cancers/ 2010-02-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-2009-year-end-results/ 2010-03-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-start-of-enrolment-in-u-s-phase-2-scc-lung-cancer-trial/ 2010-03-30T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotechr-inc-to-present-at-biofinance-2010/ 2010-04-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-publication-of-preclinical-research-on-combination-of-antiangiogenic-cancer-therapy-with-oncolytic-virotherapy/ 2010-04-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-reovirus-research-to-be-presented-at-aacr-annual-meeting/ 2010-04-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-completes-patient-enrollment-in-phase-i-portion-of-u-s-phase-i-ii-recurrent-malignant-gliomas-clinical-trial/ 2010-04-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-details-of-2010-annual-shareholder-meeting/ 2010-05-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-first-quarter-2010-results/ 2010-05-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-publication-of-phase-i-clinical-trial-results-in-clinical-cancer-research/ 2010-05-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-phase-i-colorectal-cancer-study/ 2010-05-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-reovirus-research-to-be-presented-at-asco-annual-meeting/ 2010-05-21T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-opening-of-enrollment-in-phase-3-trial-for-reolysinr-in-head-and-neck-cancers/ 2010-05-25T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-start-of-enrolment-in-u-s-phase-2-pancreatic-cancer-clinical-trial/ 2010-05-26T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-receives-approval-from-belgium-famhp-to-conduct-phase-3-trial-for-reolysinr-in-head-and-neck-cancers/ 2010-06-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotechr-inc-to-present-at-the-9th-annual-needham-healthcare-conference/ 2010-06-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-to-host-conference-call-to-discuss-updated-u-k-phase-i-ii-trial-head-and-neck-cancer-data-being-presented-at-the-asco-annual-meeting/ 2010-06-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-collaborators-present-positive-updated-u-k-phase-i-ii-trial-results-in-advanced-solid-cancers-with-a-focus-on-the-head-and-neck-at-the-asco-annual-meeting/ 2010-06-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-issuance-of-35th-u-s-patent/ 2010-06-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-receives-no-objection-letter-from-health-canada-to-conduct-phase-3-trial-of-reolysinr-in-head-and-neck-cancers/ 2010-07-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-second-quarter-2010-results/ 2010-07-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotechr-inc-to-present-at-30th-annual-canaccord-genuity-growth-conference/ 2010-08-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-randomized-phase-ii-ovarian-cancer-study-to-be-conducted-by-the-gynecologic-oncology-group-and-sponsored-by-the-national-cancer-institute/ 2010-09-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotechr-inc-to-present-at-rodman-renshaw-annual-global-investment-conference/ 2010-09-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotechr-inc-to-present-at-jmp-securities-healthcare-conference/ 2010-09-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-issuance-of-key-u-s-patent/ 2010-09-28T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotechr-inc-to-present-at-bio-investor-forum/ 2010-10-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-data-from-u-k-translational-colorectal-cancer-study-at-the-international-symposium-on-ctl-and-immunostimulation/ 2010-10-26T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-collaborators-to-present-reovirus-research-at-the-eortc-nci-aacr-meeting/ 2010-11-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-third-quarter-2010-results/ 2010-11-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-phase-i-study-in-pediatric-patients-with-relapsed-or-refractory-solid-tumors-to-be-conducted-by-the-childrens-oncology-group-and-sponsored-by-the-national-can/ 2010-11-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-publication-of-phase-i-clinical-trial-results-examining-combination-of-reolysin-and-docetaxel-in-clinical-cancer-research/ 2010-11-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-start-of-enrollment-in-randomized-phase-ii-ovarian-cancer-study/ 2010-12-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-accelerates-warrant-expiry-date/ 2010-12-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-opening-of-enrollment-in-u-s-phase-i-colorectal-cancer-study/ 2011-01-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2-arm-randomized-phase-ii-pancreatic-cancer-study/ 2011-01-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-receives-us6-8-million-from-exercise-of-warrants/ 2011-01-25T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-13th-annual-bio-ceo-investor-conference/ 2011-02-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-meets-primary-endpoint-for-first-part-of-u-s-phase-2-pancreatic-cancer-clinical-trial/ 2011-02-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-start-of-enrollment-in-randomized-phase-ii-pancreatic-cancer-study/ 2011-02-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-completion-of-enrollment-in-translational-clinical-trial-investigating-reolysin-in-patients-with-metastatic-colorectal-cancer/ 2011-02-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-rbc-capital-markets-healthcare-conference/ 2011-02-24T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-receives-7-7-million-from-exercise-of-warrants/ 2011-03-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-31st-annual-cowen-and-company-healthcare-conference/ 2011-03-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-completes-patient-enrollment-in-u-s-phase-2-clinical-trial-investigating-reolysin-in-combination-with-paclitaxel-and-carboplatin-in-head-and-neck-cancers/ 2011-03-24T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-10th-annual-needham-healthcare-conference/ 2011-03-31T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-positive-data-from-translational-clinical-trial-investigating-reolysin-in-patients-with-metastatic-colorectal-cancer/ 2011-04-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-details-of-2011-annual-shareholder-meeting/ 2011-05-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-phase-i-multiple-myeloma-cancer-study/ 2011-05-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-enters-into-commercial-supply-agreement-with-safc/ 2011-05-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-reports-correction-to-first-quarter-2011-results-press-release/ 2011-05-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-first-quarter-2011-results/ 2011-05-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-jeffries-2011-global-healthcare-conference/ 2011-06-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-reovirus-research-at-the-14th-world-conference-on-lung-cancer/ 2011-06-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-appointment-of-dr-george-m-gill-as-chief-medical-officer/ 2011-07-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-positive-reolysin-clinical-trial-results-at-the-14th-world-conference-on-lung-cancer/ 2011-07-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-second-quarter-2011-results/ 2011-07-28T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-publication-of-preclinical-research-on-synergistic-combination-of-chemotherapy-with-oncolytic-virotherapy/ 2011-08-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-to-present-at-31st-canaccord-genuity-growth-conference/ 2011-08-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-the-wedbush-2011-life-sciences-management-access-conference/ 2011-08-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-the-jmp-securities-healthcare-conference/ 2011-09-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-phase-2-clinical-trial-of-reolysin-in-combination-with-gemcitabine-in-pancreatic-cancer-reaches-primary-endpoint/ 2011-12-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-enters-into-sponsorship-agreement-with-ncic-ctg-for-randomized-phase-ii-study-in-prostate-cancer/ 2012-02-21T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-cowen-and-company-32nd-annual-health-care-conference/ 2012-03-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2011-year-end-results/ 2012-03-15T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-reovirus-research-to-be-presented-at-aacr-annual-meeting/ 2012-03-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-completes-enrollment-in-first-stage-of-phase-iii-study-in-head-and-neck-cancers/ 2012-04-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-11th-annual-needham-healthcare-conference/ 2012-04-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-enters-into-sponsorship-agreement-with-ncic-ctg-for-randomized-phase-ii-study-in-colorectal-cancer/ 2012-05-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-first-quarter-2012-results/ 2012-05-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-to-present-at-bank-of-america-merrill-lynch-2012-heath-care-conference/ 2012-05-15T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-enters-into-sponsorship-agreement-with-ncic-ctg-for-randomized-phase-ii-study-in-non-small-cell-lung-cancer/ 2012-06-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-publication-of-translational-clinical-trial-results-in-science-translational-medicine/ 2012-06-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-details-of-2012-annual-and-special-meeting-of-shareholders/ 2012-06-15T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-bloom-burton-co-healthcare-investor-conference/ 2012-06-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-announces-independent-data-monitoring-committee-recommends-continued-enrollment-in-phase-iii-study-of-reolysin-in-head-and-neck-cancers-following-review-of-safety-data/ 2012-06-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-enters-into-sponsorship-agreement-with-ncic-ctg-for-randomized-phase-ii-study-in-advanced-and-metastatic-breast-cancers/ 2012-06-21T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-second-quarter-2012-results/ 2012-08-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-completes-patient-enrollment-in-u-k-phase-i-clinical-trial-investigating-reolysin-in-combination-with-cyclophosphamide-in-patients-with-advanced-malignances/ 2012-08-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-completes-patient-enrollment-in-u-s-phase-i-clinical-trial-investigating-reolysin-in-combination-with-folfiri-in-patients-with-colorectal-cancer/ 2012-08-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-provides-update-on-phase-iii-study-of-reolysin-in-head-and-neck-cancers/ 2012-09-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-meets-primary-endpoint-for-first-stage-of-u-s-phase-2-squamous-cell-lung-cancer-clinical-trial/ 2012-09-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-the-appointment-of-dr-alan-j-tuchman-as-chief-medical-officer/ 2012-09-28T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-addition-to-senior-management-team-2/ 2012-11-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-positive-top-line-reolysin-data-for-first-endpoint-in-randomized-phase-iii-study-in-head-and-neck-cancers/ 2012-12-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-positive-reolsyin-clinical-trial-data-presented-at-asco-gastrointestinal-cancers-symposium/ 2013-01-28T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-additional-positive-reolsyin-clinical-trial-data-from-phase-2-study-in-squamous-cell-carcinoma-of-the-lung/ 2013-02-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-common-share-offering/ 2013-02-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-addition-to-senior-management-team/ 2013-02-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-pricing-of-common-share-offering/ 2013-02-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-rbc-capital-markets-2013-healthcare-conference/ 2013-02-25T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-closing-of-common-share-offering/ 2013-02-25T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-completes-patient-enrollment-in-u-s-phase-2-study-of-reolysin-in-non-small-cell-lung-cancer/ 2013-03-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2012-year-end-results/ 2013-03-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-meets-primary-overall-statistical-endpoint-in-u-s-phase-2-study-of-reolysin-in-squamous-cell-lung-cancer/ 2013-03-28T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-12th-annual-needham-healthcare-conference/ 2013-04-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-details-of-2013-annual-and-special-meeting-of-shareholders/ 2013-05-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-first-quarter-2013-results/ 2013-05-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-director-election-results-from-its-annual-and-special-meeting-of-shareholders/ 2013-05-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-bank-of-america-merrill-lynch-health-care-conference/ 2013-05-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-meets-primary-endpoint-for-first-stage-of-u-s-phase-2-metastatic-melanoma-trial/ 2013-05-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-to-present-at-2013-jefferies-global-healthcare-conference/ 2013-06-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-the-2013-wedbush-pacgrow-life-sciences-management-access-conference/ 2013-08-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-announces-participation-in-upcoming-conferences-3/ 2013-09-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-positive-final-tumour-response-data-for-u-s-phase-2-study-of-reolysin-in-squamous-cell-lung-cancer/ 2013-09-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-positive-clinical-trial-data-at-the-15th-annual-world-conference-on-lung-cancer/ 2013-10-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-progression-free-survival-data-for-phase-2-study-of-reolysin-in-squamous-cell-lung-cancer/ 2013-10-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-positive-data-correlating-specific-biomarkers-with-survival-in-nsclc-patients-treated-with-reolysin-carboplatin-and-paclitaxel/ 2013-10-28T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-third-quarter-2013-results/ 2013-11-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-positive-top-line-data-from-reo-018-randomized-study-of-reolysin-in-head-and-neck-cancers/ 2013-11-21T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-to-present-at-the-25th-annual-piper-jaffray-healthcare-conference/ 2013-12-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-participate-in-2014-rbc-capital-markets-global-healthcare-conference/ 2014-02-25T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-initial-us1-0-million-investment-and-up-to-us25-0-million-common-share-purchase-agreement-with-lincoln-park-capital-fund-llc/ 2014-02-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-participate-in-the-34th-annual-cowen-and-company-healthcare-conference/ 2014-03-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2013-year-end-results/ 2014-03-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-participate-in-13th-annual-needham-healthcare-conference/ 2014-04-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-preclinical-research-in-multiple-myeloma-and-melanoma-at-aacr-2014-annual-meeting/ 2014-04-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-additional-data-from-reo-018-randomized-study-of-reolysin-in-head-and-neck-cancers/ 2014-04-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-translational-brain-cancer-clinical-data-and-immunomodulatory-preclinical-research-at-uk-oncolytic-virus-conference/ 2014-04-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-preclinical-research-on-liver-cancer-at-uk-oncolytic-virus-conference/ 2014-04-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-head-and-neck-cancer-biomarker-preclinical-research-at-uk-oncolytic-virus-conference/ 2014-04-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-first-quarter-2014-results/ 2014-05-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-positive-brain-cancer-clinical-trial-data-at-the-50th-annual-asco-meeting/ 2014-05-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-nomination-of-two-new-directors/ 2014-05-21T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-participate-in-jefferies-2014-global-healthcare-conference/ 2014-06-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-details-of-2014-annual-meeting-of-shareholders/ 2014-06-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-director-election-results-from-its-annual-meeting-of-shareholders-2/ 2014-06-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-completion-of-patient-enrollment-in-u-s-randomized-phase-ii-pancreatic-cancer-study/ 2014-07-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-second-quarter-2014-results/ 2014-08-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-announces-participation-in-upcoming-conferences-2/ 2014-08-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-participate-in-the-baird-2014-health-care-conference/ 2014-09-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/c-o-r-r-e-c-t-i-o-n-from-source-oncolytics-biotech-inc-2/ 2014-09-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-overall-and-kras-mutated-patient-data-from-u-s-randomized-phase-2-pancreatic-cancer-study/ 2014-09-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-amendment-to-common-share-purchase-agreement-with-lincoln-park-capital-fund-llc/ 2014-10-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-entry-into-20-million-at-the-market-equity-distribution-agreement-with-canaccord-genuity-inc/ 2014-10-24T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-receipt-of-nasdaq-notice-of-deficiency/ 2014-11-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-third-quarter-2014-results/ 2014-11-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-participate-in-the-stifel-2014-healthcare-conference/ 2014-11-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-filing-for-orphan-drug-designation-with-the-u-s-fda-for-pancreatic-and-ovarian-cancers/ 2014-12-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-reolysin-and-checkpoint-inhibitor-combination-preclinical-data-at-aacr-tumor-immunology-and-immunotherapy-conference/ 2014-12-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-filing-for-orphan-designation-with-the-ema-for-pancreatic-and-ovarian-cancers/ 2014-12-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-filing-for-orphan-drug-designation-with-the-u-s-fda-for-high-grade-gliomas-in-pediatric-patients/ 2015-02-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-ovarian-cancer/ 2015-02-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-pancreatic-cancer/ 2015-02-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-completion-of-enrollment-in-randomized-phase-ii-colorectal-cancer-study/ 2015-02-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-cancer-of-the-fallopian-tube/ 2015-03-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-primary-peritoneal-cancer/ 2015-03-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-preclinical-data-on-the-combination-of-reolysin-and-radiotherapy-in-melanoma-at-the-irish-association-for-cancer-research-conference/ 2015-03-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2014-year-end-results/ 2015-03-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-status-from-the-ema-for-ovarian-cancer/ 2015-03-25T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-presents-at-the-2015-immune-checkpoint-inhibitors-meeting/ 2015-03-26T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-filing-for-orphan-drug-designation-with-the-u-s-fda-for-gastric-cancer/ 2015-04-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-participate-in-the-14th-annual-needham-healthcare-conference/ 2015-04-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-presents-at-uk-immuno-oncology-meeting/ 2015-04-15T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-malignant-gliomas/ 2015-04-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-reolysin-preclinical-data-at-the-2015-aacr-annual-meeting/ 2015-04-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-extension-to-regain-compliance-with-nasdaqs-minimum-bid-price-rule/ 2015-04-28T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-status-from-the-ema-for-pancreatic-cancer/ 2015-04-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-receipt-of-orphan-drug-designation-from-the-u-s-fda-for-gastric-cancer/ 2015-05-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2015-first-quarter-results/ 2015-05-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-phase-1-study-in-pediatric-patients-with-brain-tumors/ 2015-05-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-participate-in-the-ld-micro-invitational-conference/ 2015-06-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-details-of-2015-annual-meeting-of-shareholders/ 2015-06-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/c-o-r-r-e-c-t-i-o-n-oncolytics-biotech-inc/ 2015-06-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-provides-update-at-agm-on-planned-registration-program-for-reolysin/ 2015-06-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-director-election-results-from-its-annual-meeting-of-shareholders/ 2015-06-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-voting-results-from-its-annual-meeting-of-shareholders-3/ 2015-06-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-reolysin-preclinical-data-at-the-9th-international-conference-on-oncolytic-virus-therapeutics/ 2015-06-15T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-final-data-from-reo-017-clinical-study-in-pancreatic-cancer/ 2015-07-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2015-second-quarter-results/ 2015-08-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-participate-in-the-35th-annual-canaccord-genuity-growth-conference/ 2015-08-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-completion-of-enrollment-in-randomized-phase-ii-non-small-cell-lung-cancer-study/ 2015-08-26T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-to-present-survival-data-from-reo-016-study-in-non-small-cell-lung-cancer/ 2015-08-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-participate-in-the-baird-2015-healthcare-conference/ 2015-09-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-data-from-clinical-study-in-multiple-myeloma/ 2015-09-25T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-completion-of-enrollment-in-randomized-phase-ii-prostate-cancer-study/ 2015-10-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-participate-in-the-14th-annual-bio-investor-forum/ 2015-10-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-phase-1b-study-in-advanced-pancreatic-cancer/ 2015-10-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-receipt-of-qualification-for-trading-on-the-otcqx-and-nasdaq-notice-of-delisting/ 2015-10-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2015-third-quarter-results/ 2015-11-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/c-o-r-r-e-c-t-i-o-n-from-source-oncolytics-biotech-inc/ 2015-11-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-to-present-at-ld-micro-growth-conference/ 2015-12-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-multiple-myeloma-data-at-57th-american-society-of-hematology-annual-meeting/ 2015-12-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-first-patients-treated-in-phase-1b-study-in-advanced-pancreatic-cancer/ 2016-01-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-announces-participation-in-upcoming-conferences/ 2016-02-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-2015-year-end-results/ 2016-03-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-reports-data-from-randomized-phase-2-study-of-reolysin-in-ovarian-cancer/ 2016-03-21T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-filing-of-management-information-circular-and-details-of-2016-annual-general-meeting/ 2016-03-24T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-reports-updated-data-from-randomized-phase-2-study-of-reolysin-in-pancreatic-cancer/ 2016-04-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-reolysin-preclinical-research-at-the-2016-aacr-annual-meeting/ 2016-04-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-to-participate-in-the-bloom-burton-co-healthcare-investor-conference/ 2016-04-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-formation-of-science-and-technology-committee/ 2016-04-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-details-of-2016-annual-meeting-of-shareholders/ 2016-05-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-presentation-of-reolysin-preclinical-research-at-the-2016-asgct-annual-meeting/ 2016-05-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-voting-results-from-its-annual-meeting-of-shareholders-2/ 2016-05-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2016-first-quarter-results/ 2016-05-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-reports-preliminary-data-from-randomized-phase-ii-study-of-reolysin-in-colorectal-cancer/ 2016-05-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-reports-preliminary-data-from-randomized-phase-ii-study-of-reolysin-in-non-small-cell-lung-cancer/ 2016-05-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-phase-2-study-in-female-patients-with-colorectal-cancer-metastatic-to-the-liver/ 2016-06-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2016-second-quarter-results/ 2016-08-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-announces-participation-in-the-canaccord-genuity-36th-annual-growth-conference/ 2016-08-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-reports-additional-data-from-randomized-phase-ii-study-of-reolysin-in-non-small-cell-lung-cancer/ 2016-08-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-announces-participation-in-the-4th-annual-immuno-oncology-summit/ 2016-08-30T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-announces-participation-in-the-2016-bio-investor-forum/ 2016-10-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/media-advisory-oncolytics-biotech-inc-announces-management-team-changes/ 2016-11-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2016-third-quarter-results/ 2016-11-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-appointment-of-new-chief-medical-officer/ 2016-11-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-change-to-board-of-directors/ 2016-12-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-collaborators-present-initial-results-from-reo-019-study-in-multiple-myeloma-combining-reolysin-bortezomib-and-dexamethasone-at-the-ash-annual-meeting/ 2016-12-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-appoints-dr-matt-coffey-to-the-role-of-president-and-ceo/ 2017-01-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-canadian-cancer-trials-group-to-present-final-randomized-data-from-phase-2-metastatic-breast-cancer-study-at-aacr-2017-annual-meeting/ 2017-03-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2016-year-end-results/ 2017-03-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-enters-into-first-in-class-collaboration-with-myeloma-uk-and-celgene-using-reolysin-in-combination-with-imnovid-or-revlimid-in-patients-with-myeloma/ 2017-03-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-s-reolysin-provides-statistically-significant-improvement-in-overall-survival-in-canadian-cancer-trials-group-sponsored-randomized-phase-2-study-in-metastatic-brea/ 2017-03-31T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-s-reolysin-more-than-doubles-overall-survival-in-patients-with-mutated-p53-metastatic-breast-cancer/ 2017-04-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-registration-pathway-and-clinical-development-plan/ 2017-04-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-to-present-at-the-sixth-annual-bloom-burton-co-healthcare-investor-conference/ 2017-04-26T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-details-of-2017-annual-meeting-of-shareholders/ 2017-04-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-voting-results-from-its-annual-meeting-of-shareholders/ 2017-05-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2017-first-quarter-results/ 2017-05-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-asco-abstracts-and-preliminary-data-for-studies-in-pancreatic-and-prostate-cancers/ 2017-05-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-proposed-public-offering/ 2017-05-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-participation-in-world-immunotherapy-congress-usa-2017/ 2017-05-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-prices-public-offering-of-units/ 2017-05-24T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-closing-of-public-offering-of-units/ 2017-06-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-opens-u-s-based-office-in-san-diego/ 2017-06-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-appoints-andrew-de-guttadauro-president-of-oncolytics-biotech-u-s-inc/ 2017-06-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-reolysin-safety-data-in-combination-with-chemotherapy-at-esmo-2017-congress/ 2017-07-26T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-to-present-at-the-canaccord-genuity-37th-annual-growth-conference/ 2017-08-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2017-second-quarter-results/ 2017-08-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-the-presentation-of-reolysin-clinical-data-at-esmo-2017-congress/ 2017-09-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-first-patient-treated-in-muk-eleven-study/ 2017-09-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-successful-end-of-phase-2-meeting-with-fda-for-reolysin-in-metastatic-breast-cancer/ 2017-09-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-at-the-phacilitate-immuno-oncology-frontiers-conference/ 2017-09-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-at-the-2017-bio-investor-forum/ 2017-10-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-appoints-deborah-brown-to-board-of-directors/ 2017-11-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-2017-third-quarter-results/ 2017-11-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-and-adlai-nortye-enter-into-usd-86-6-million-regional-licensing-agreement-for-reolysin/ 2017-11-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-establishes-scientific-advisory-board-focused-on-reolysin-registration-study-in-metastatic-breast-cancer/ 2017-11-30T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-at-the-oncolytic-virotherapy-summit/ 2017-12-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-receives-favorable-final-advice-letter-from-the-european-medicines-agency-for-reolysin-in-metastatic-breast-cancer/ 2017-12-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-poster-presentation-at-the-2018-gastrointestinal-cancers-symposium-sponsored-by-asco-in-patients-with-relapsed-metastatic-adenocarcinoma-of-the-pancreas/ 2017-12-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-abstract-for-poster-presentation-at-the-2018-gastrointestinal-cancers-symposium-sponsored-by-asco-in-patients-with-relapsed-metastatic-adenocarcinoma-of-the-pancreas/ 2018-01-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-poster-presentation-at-the-2018-gastrointestinal-cancers-symposium-sponsored-by-asco-in-patients-with-relapsed-metastatic-adenocarcinoma-of-the-pancreas/ 2018-01-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-named-to-the-2018-otcqx-best-50/ 2018-01-25T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-plans-to-apply-to-list-common-shares-on-the-nasdaq-capital-market/ 2018-01-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-host-conference-call-outlining-the-treatment-paradigm-of-metastatic-breast-cancer-subtypes-and-provide-topline-information-on-its-phase-3-registration-study-with-reolysinr/ 2018-02-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-present-at-the-rbc-capital-markets-2018-healthcare-conference/ 2018-02-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-results-from-special-meeting-of-shareholders/ 2018-02-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-present-reolysinr-at-the-2018-precision-breast-cancer-world-rd-summit/ 2018-02-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-chief-medical-officer-to-facilitate-roundtable-discussion-at-the-us-immuno-oncology-strategy-meeting/ 2018-03-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-inc-announces-2017-year-end-results/ 2018-03-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-publication-of-reolysinr-abstract-for-the-aacr-2018-annual-meeting/ 2018-03-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-scientist-selected-to-participate-in-the-society-of-immunotherapy-of-cancers-sitc-metior-incubator-program/ 2018-03-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-present-at-the-microcap-conference/ 2018-04-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-presents-positive-reolysinr-data-in-combination-with-keytruda-and-anti-cd73-at-international-oncolytic-virus-conference-2018/ 2018-04-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-management-change/ 2018-04-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-demonstrates-positive-data-in-two-posters-at-aacr-annual-meeting-2018/ 2018-04-18T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-details-of-2018-annual-general-meeting-of-shareholders/ 2018-04-26T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-voting-results-from-its-annual-general-meeting-of-shareholders/ 2018-05-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-2018-first-quarter-results/ 2018-05-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-publication-of-reolysin-abstract-for-the-asco-2018-annual-meeting/ 2018-05-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-collaboration-between-merck-and-northwestern-university-combining-keytruda-and-reolysin-in-a-phase-2-second-line-pancreatic-cancer-study/ 2018-05-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-has-applied-to-list-its-common-shares-on-nasdaq-and-announces-share-consolidation/ 2018-05-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-research-collaboration-with-the-keck-school-of-medicine-of-usc-combining-reolysin-with-keytruda-velcade-and-dexamethasone/ 2018-05-25T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-new-otcqx-ticker-symbol/ 2018-05-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-public-offering-of-common-shares/ 2018-05-31T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-prices-usd-8000000-million-public-offering-of-common-shares/ 2018-06-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-listing-on-nasdaq-capital-market/ 2018-06-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-poster-presentation-demonstrating-the-ability-of-reolysin-to-promote-and-predict-response-to-checkpoint-inhibitors-at-asco-2018-annual-meeting/ 2018-06-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-closes-usd-8-9-million-public-offering-of-common-shares/ 2018-06-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-at-the-canaccord-genuity-38th-annual-growth-conference/ 2018-07-31T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-2018-second-quarter-results/ 2018-08-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-investigator-sponsored-multiple-myeloma-study-combining-reolysin-and-nivolumab-opdivo-with-standard-of-care/ 2018-09-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-provides-corporate-and-clinical-update/ 2018-09-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-at-the-ladenburg-thalmann-2018-healthcare-conference/ 2018-09-26T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-enters-into-common-stock-purchase-agreement-for-up-to-us26-million-with-lincoln-park-capital-llc/ 2018-09-28T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-a-publication-demonstrating-that-intravenously-delivered-oncolytic-viruses-effectively-target-tumors-even-in-the-presence-of-neutralizing-antibodies/ 2018-10-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-publication-of-positive-clinical-results-for-pelareorep-in-abstract-for-esmo-2018-congress/ 2018-10-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-positive-clinical-trial-results-for-pelareorep-in-patients-with-kras-mutant-metastatic-colorectal-cancer-for-presentation-at-esmo-2018/ 2018-10-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-establishes-new-at-the-market-facility-3/ 2018-10-24T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-abstract-for-ash-annual-meeting-exposition-demonstrating-pelareorep-increases-pd-l1-expression-when-combined-with-a-proteasome-inhibitor/ 2018-11-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-third-quarter-financial-results-and-corporate-highlights/ 2018-11-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-presentation-at-the-society-for-immunotherapy-of-cancer-2018-annual-meeting-showcasing-upregulation-of-pd-l1-expression-with-reovirus-infection/ 2018-11-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-2018-third-quarter-financial-results-and-provides-corporate-update/ 2018-11-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-attendance-of-upcoming-conferences/ 2018-11-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-first-patient-treated-in-phase-2-study-combining-pelareorep-and-keytruda-in-advanced-pancreatic-cancer/ 2018-11-26T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-appointment-of-rita-laeufle-m-d-as-chief-medical-officer/ 2018-11-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-increased-pd-l1-expression-when-combining-pelareorep-with-a-proteasome-inhibitor-in-poster-presentation-at-the-60th-american-society-of-hematology-annual-meeting/ 2018-12-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-first-patient-treated-in-study-combining-pelareorep-carfilzomib-and-the-checkpoint-inhibitor-opdivo-in-multiple-myeloma/ 2018-12-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-present-at-the-21st-annual-bio-ceo-investor-conference/ 2019-02-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-presents-biomarker-data-in-second-line-pancreatic-cancer-at-aacr/ 2019-02-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-host-conference-call-to-discuss-year-end-financial-results-and-operational-highlights/ 2019-03-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-r-announces-2018-year-end-results-and-operational-highlights/ 2019-03-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-r-announces-a-publication-highlighting-synergistic-effect-of-pelareorep-with-a-proteasome-inhibitor-in-preclinical-models-of-multiple-myeloma/ 2019-03-28T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-r-presents-positive-clinical-biomarker-data-at-the-american-association-for-cancer-research-annual-meeting-2019/ 2019-04-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-present-at-the-18th-annual-needham-healthcare-conference/ 2019-04-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-host-key-opinion-leader-meeting-on-the-emerging-role-of-biomarkers-and-oncolytic-viruses-in-the-treatment-of-cancer/ 2019-04-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-present-at-the-2019-bloom-burton-co-healthcare-investor-conference/ 2019-04-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-details-of-2019-annual-general-meeting-of-shareholders/ 2019-04-25T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-voting-results-from-the-annual-general-meeting-of-shareholders/ 2019-05-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-r-reports-2019-first-quarter-financial-results-and-operational-highlights/ 2019-05-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-r-publishes-abstract-highlighting-additional-biomarker-analyses-at-the-2019-american-society-of-clinical-oncology-annual-meeting/ 2019-05-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-present-at-the-9th-annual-ld-micro-invitational-investor-conference/ 2019-05-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-r-to-host-conference-call-to-discuss-co-development-agreement-with-pfizer-and-merck-kgaa/ 2019-06-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-public-offering-of-common-shares-and-warrants/ 2019-08-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-reports-2019-second-quarter-financial-results-and-operational-highlights/ 2019-08-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/correction-oncolytics-biotechr-announces-pricing-of-its-usd-3-7m-cdn-4-9m-public-offering-of-common-share-and-warrants/ 2019-08-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-pricing-of-its-public-offering-of-common-share-and-warrants/ 2019-08-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-closing-of-its-public-offering-of-common-shares-and-warrants/ 2019-08-16T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-host-corporate-update-call-to-discuss-recent-highlights-and-expanded-catalysts-and-milestones/ 2019-09-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-present-at-the-h-c-wainwright-21st-annual-global-investment-conference/ 2019-09-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-present-at-the-ladenburg-thalmann-healthcare-conference/ 2019-09-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-receives-nasdaq-notification-letter/ 2019-09-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-upcoming-conference-participation/ 2019-09-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-upcoming-presentation-at-the-12th-annual-international-oncolytics-virus-conference/ 2019-09-25T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-ceo-matt-coffey-honored-with-scientific-achievement-and-innovation-award-by-bioalberta/ 2019-09-30T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-abstract-to-be-presented-at-the-34th-annual-meeting-of-the-society-for-immunotherapy-of-cancer/ 2019-10-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-presents-clinical-data-highlighting-the-effectiveness-of-intravenous-delivery-to-and-replication-of-pelareorep-in-tumors/ 2019-10-15T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-appoints-experienced-financial-and-strategic-leader-leonard-kruimer-to-board-of-directors/ 2019-10-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-provides-update-on-partner-adlai-nortyes-clinical-progress/ 2019-10-31T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-to-host-conference-call-to-discuss-third-quarter-financial-results-and-operational-highlights/ 2019-11-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-publication-of-positive-reo-024-study-results-for-pelareorep-in-combination-with-keytrudar-in-patients-with-advanced-pancreatic-adenocarcinoma/ 2019-11-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-abstract-published-for-the-61st-annual-meeting-exposition-of-the-american-society-of-hematology/ 2019-11-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-reports-2019-third-quarter-financial-results-and-operational-highlights/ 2019-11-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-exercise-of-warrants/ 2019-11-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-presents-clinical-data-at-the-fifth-annual-oncolytic-virotherapy-conference-highlighting-definitive-evidence-of-systemic-delivery-and-replication-of-pelareorep-in-tumor-tissue/ 2019-12-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-regains-compliance-with-nasdaq-minimum-bid-price-requirement/ 2019-12-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-positive-multiple-myeloma-data-presented-at-the-61st-annual-meeting-exposition-of-the-american-society-of-hematology/ 2019-12-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-abstract-outlining-potential-new-biomarker-to-be-presented-at-the-2020-gastrointestinal-cancers-symposium/ 2019-12-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-key-opinion-leader-call-conducted-by-roth-capital-partners-to-discuss-multiple-myeloma/ 2020-01-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-provides-recap-of-key-opinion-leader-call-highlighting-pelareoreps-unique-ability-to-activate-the-immune-system-in-late-stage-multiple-myeloma/ 2020-01-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-publication-of-an-abstract-for-the-2020-gastrointestinal-cancers-symposium-highlighting-ceacam6-as-a-potential-prognostic-biomarker-candidate-for-pancreatic-cancer/ 2020-01-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-statistically-significant-data-identifying-ceacam6-as-a-prospective-prognostic-biomarker-for-pelareorep-in-the-treatment-of-pancreatic-adenocarcinoma/ 2020-01-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2019-financial-results-and-operational-highlights/ 2020-02-28T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-fourth-quarter-and-full-year-2019-financial-results-and-operational-highlights/ 2020-03-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-publication-of-pelareoreps-clinical-benefit-against-kras-mutated-colorectal-cancer/ 2020-04-02T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-updates-clinical-development-and-operations-activities-during-the-covid-19-pandemic/ 2020-04-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-changes-to-annual-general-meeting/ 2020-04-30T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-2020-first-quarter-financial-results-and-operational-highlights/ 2020-05-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-2/ 2020-05-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-at-the-rbc-global-healthcare-conference/ 2020-05-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-publication-of-abstracts-at-the-2020-american-society-of-clinical-oncology-virtual-annual-meeting/ 2020-05-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-presents-clinical-proof-of-concept-data-in-multiple-myeloma-at-the-asco-virtual-annual-meeting/ 2020-05-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-provides-recap-of-key-opinion-leader-call-highlighting-the-induction-of-rapid-and-persistent-immune-responses-with-systemic-pelareorep-treatment/ 2020-06-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-establishes-new-at-the-market-facility-2/ 2020-06-15T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-investigator-sponsored-phase-2-trial-evaluating-pelareorep-anti-pd-1-combination-treatment-in-triple-negative-breast-cancer/ 2020-06-25T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-second-quarter-financial-results-and-operational-highlights-2/ 2020-07-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-2020-second-quarter-financial-results-and-operational-highlights/ 2020-08-04T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-virtual-fireside-chat-at-the-canaccord-genuity-40th-annual-growth-conference/ 2020-08-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-doses-first-patient-in-phase-2-irene-study-evaluating-pelareorep-anti-pd-1-combination-treatment-in-triple-negative-breast-cancer/ 2020-08-26T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-upcoming-presentations-at-investor-conferences/ 2020-09-01T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-bio-investor-forum-digital/ 2020-10-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-appoints-richard-vile-ph-d-to-its-scientific-advisory-board/ 2020-10-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-third-quarter-financial-results-and-operational-highlights-2/ 2020-11-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-abstract-publication-and-upcoming-oral-presentation-at-the-2020-society-of-neuro-oncology-annual-meeting/ 2020-11-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-2020-third-quarter-development-highlights-and-financial-results/ 2020-11-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-positive-clinical-results-against-glioblastoma-multiforme-at-the-2020-society-of-neuro-oncology-annual-meeting/ 2020-11-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-preclinical-data-demonstrating-the-synergistic-anti-cancer-activity-of-pelareorep-combined-with-car-t-cell-therapy-in-solid-tumors/ 2021-02-23T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-operational-highlights/ 2021-02-26T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-establishes-new-at-the-market-facility/ 2021-03-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-fourth-quarter-and-full-year-2020-financial-results-and-operational-highlights/ 2021-03-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-a-panel-discussion-at-the-canaccord-genuity-horizons-in-oncology-virtual-conference/ 2021-04-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-presents-preclinical-data-on-pelareorep-based-combination-therapies-at-the-aacr-annual-meeting/ 2021-04-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-upcoming-presentation-at-the-american-society-of-clinical-oncology-annual-meeting/ 2021-04-29T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-annual-general-meeting/ 2021-04-30T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-2021-first-quarter-development-highlights-and-financial-results/ 2021-05-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders/ 2021-05-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-virtual-fireside-chat-at-the-2021-rbc-capital-markets-global-healthcare-conference/ 2021-05-13T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-clinical-and-biomarker-data-demonstrating-clinical-proof-of-concept-for-pelareorep-checkpoint-inhibitor-combination-in-pancreatic-cancer/ 2021-05-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-at-the-ladenburg-thalmann-healthcare-conference/ 2021-06-30T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-second-quarter-financial-results-and-operational-highlights/ 2021-07-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-2021-second-quarter-development-highlights-and-financial-results/ 2021-08-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-virtual-fireside-chat-at-the-canaccord-genuity-41st-annual-growth-conference/ 2021-08-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-preclinical-data-demonstrating-the-synergistic-immunotherapeutic-effects-of-pelareorep-combined-with-radiotherapy/ 2021-09-20T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechpartner-adlai-nortye-doses-first-patient-in-chinese-bridging-trial-evaluating-pelareorep-paclitaxel-combination-treatment-in-breast-cancer/ 2021-10-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-third-quarter-financial-results-and-operational-highlights/ 2021-10-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-2021-third-quarter-development-highlights-and-financial-results/ 2021-11-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-phase-2-triple-negative-breast-cancer-trial-update-at-the-2021-san-antonio-breast-cancer-symposium/ 2021-11-19T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-presents-positive-interim-safety-update-from-phase-2-triple-negative-breast-cancer-trial-at-the-2021-san-antonio-breast-cancer-symposium/ 2021-12-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-the-presentation-of-preclinical-data-demonstrating-the-synergistic-anti-leukemic-effects-of-pelareorep-combined-with-azacitidine-at-the-2021-american-society-of-hema/ 2021-12-15T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-promotes-thomas-c-heineman-m-d-ph-d-to-chief-medical-officer/ 2021-12-21T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-releases-a-letter-to-shareholders-2021-review-and-2022-outlook/ 2022-01-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-partner-adlai-nortye-advances-to-the-second-dose-escalation-cohort-of-the-chinese-bridging-trial-evaluating-pelareorep-paclitaxel-combination-treatment-in-breast-cancer/ 2022-01-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights/ 2022-02-22T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-fourth-quarter-and-full-year-2021-financial-results-and-recent-operational-highlights/ 2022-03-03T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-phase-1b-data-demonstrating-clinical-proof-of-concept-for-pelareorep-proteasome-inhibitor-combination-in-multiple-myeloma-in-an-abstract-at-the-aacr-annual-meeting/ 2022-03-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-upcoming-poster-presentation-at-the-aacr-annual-meeting/ 2022-03-09T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-publication-of-preclinical-and-patient-data-demonstrating-pelareoreps-stimulation-of-natural-killer-cell-anti-cancer-activity/ 2022-03-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-partner-adlai-nortye-advances-chinese-bridging-trial-of-pelareorep-paclitaxel-combination-treatment-in-breast-cancer-to-final-dosing-cohort/ 2022-03-24T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-letter-to-shareholders-update-on-recent-progress/ 2022-04-06T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-positive-long-term-survival-data-from-phase-1b-glioblastoma-multiforme-trial-at-the-aacr-annual-meeting/ 2022-04-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-presents-new-data-demonstrating-durable-clinical-benefit-in-relapsed-refractory-multiple-myeloma-patients-at-the-aacr-annual-meeting/ 2022-04-08T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-a-fireside-chat-at-the-canaccord-genuity-horizons-in-oncology-virtual-conference/ 2022-04-12T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-publication-of-preclinical-data-demonstrating-the-synergistic-anti-cancer-activity-of-pelareorep-combined-with-car-t-cell-therapy-in-solid-tumors-in-science-translat/ 2022-04-14T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-at-the-bloom-burton-co-healthcare-investor-conference/ 2022-04-21T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and-recent-operational-highlights/ 2022-04-28T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-first-quarter-2022-financial-results-and-recent-operational-highlights/ 2022-05-05T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-a-fireside-chat-at-the-2022-rbc-capital-markets-global-healthcare-conference/ 2022-05-10T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-and-appoints-james-t-parsons-to-its-board-of-directors/ 2022-06-17T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-second-quarter-financial-results-and-recent-operational-highlights/ 2022-07-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-second-quarter-2022-financial-results-and-recent-operational-highlights/ 2022-08-11T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-appoints-jonathan-rigby-to-its-board-of-directors/ 2022-09-07T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-third-quarter-financial-results-and-recent-operational-highlights/ 2022-10-27T12:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-third-quarter-2022-financial-results-and-recent-operational-highlights/ 2022-12-08T09:32:51+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechs-chinese-development-partner-adlai-nortye-presents-interim-clinical-data-further-demonstrating-the-anti-cancer-activity-of-pelareorep-paclitaxel-combination-therapy-in/ 2022-12-08T16:54:21+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-receives-fda-fast-track-designation-for-the-treatment-of-advanced-metastatic-pancreatic-cancer/ 2023-06-14T16:09:12+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-presents-updated-clinical-data-at-sitc-annual-meeting-showing-a-69-objective-response-rate-and-confirmed-complete-response-in-goblet-studys-pancreatic-cancer-cohort/ 2023-06-14T16:09:35+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-interim-results-from-phase-1-2-goblet-study-showing-a-70-objective-response-rate-in-pancreatic-cancer-at-the-sitc-annual-meeting/ 2023-06-14T16:09:51+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-upcoming-presentations-at-the-society-for-immunotherapy-of-cancer-37th-annual-meeting/ 2023-06-14T16:10:19+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-achieves-success-criteria-for-efficacy-in-the-pancreatic-cancer-cohort-of-goblet/ 2023-06-14T16:10:27+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-provides-positive-safety-update-on-the-third-line-metastatic-colorectal-cancer-cohort-of-its-multi-indication-phase-1-2-gastrointestinal-cancer-trial/ 2023-06-14T16:10:49+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-provides-positive-safety-update-on-the-pancreatic-cancer-cohort-of-its-multi-indication-phase-1-2-gastrointestinal-cancer-trial/ 2023-06-14T16:11:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-provides-enrollment-update-on-multi-indication-phase-1-2-gastrointestinal-cancer-trial-at-the-2022-american-society-of-clinical-oncology-gastrointestinal-cancers-symposium/ 2023-06-14T16:11:55+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-doses-first-patient-in-phase-1-2-goblet-study-evaluating-pelareorep-anti-pd-l1-combination-therapies-in-gastrointestinal-cancers/ 2023-06-14T16:12:10+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-collaborates-with-roche-and-aio-to-initiate-a-phase-1-2-gastrointestinal-cancer-trial-combining-pelareorep-with-roches-anti-pd-l1-checkpoint-inhibitor/ 2023-06-14T16:12:26+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-doses-first-patient-in-phase-2-bracelet-1-study-evaluating-pelareorep-based-combination-therapies-in-metastatic-breast-cancer/ 2023-06-14T16:13:28+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-and-precog-announce-collaboration-for-bracelet-1-pre0113-study-in-metastatic-breast-cancer/ 2023-06-14T16:13:54+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-r-announces-study-to-investigate-combination-of-pelareorep-and-avelumab-in-metastatic-breast-cancer-in-collaboration-with-merck-kgaa-darmstadt-germany-and-pfizer/ 2023-06-14T16:15:05+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-receives-special-protocol-assessment-agreement-from-fda-for-phase-3-clinical-trial-of-pelareorep-in-metastatic-breast-cancer/ 2023-06-14T16:15:17+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-inc-announces-fda-fast-track-designation-for-reolysin-in-metastatic-breast-cancer/ 2023-06-14T16:15:28+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-presentations-at-the-upcoming-san-antonio-breast-cancer-symposium/ 2023-06-14T16:16:10+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-and-solti-present-new-clinical-biomarker-data-demonstrating-pelareoreps-potential-to-improve-the-prognosis-of-breast-cancer-patients-at-the-esmo-breast-cancer-meeting/ 2023-06-14T16:16:22+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-and-solti-announce-upcoming-poster-presentation-at-the-european-society-for-medical-oncology-breast-cancer-meeting/ 2023-06-14T16:16:36+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-and-solti-achieve-primary-endpoint-in-aware-1-study/ 2023-06-14T16:17:23+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-key-opinion-leader-webinar-to-discuss-aware-1-data-the-immunotherapeutic-effects-of-pelareorep-in-breast-cancer-and-its-synergistic-activity-with-car-t-cells-in-soli/ 2023-06-14T16:17:34+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-upcoming-presentations-at-the-aacr-annual-meeting/ 2023-06-14T16:17:49+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-and-solti-report-clinical-synergy-of-pelareorep-with-checkpoint-inhibitors-at-the-2020-san-antonio-breast-cancer-symposium/ 2023-06-14T16:18:01+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-aware-1-data-and-provide-updates-on-phase-2-bracelet-1-and-irene-trials-at-the-2020-san-antonio-breast-cancer-symposium/ 2023-06-14T16:18:27+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-and-solti-present-clinical-breast-cancer-data-highlighting-pelareorep-induced-anti-tumor-t-cell-responses-at-the-society-for-immunotherapy-of-cancer-annual-meeting/ 2023-06-14T16:18:41+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-presents-clinical-data-supporting-a-predictive-biomarker-of-pelareorep-response-in-breast-cancer-at-the-esmo-breast-cancer-virtual-meeting/ 2023-06-14T16:18:51+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-clinical-findings-of-pelareorep-induced-immune-response-in-breast-tumors-at-the-esmo-breast-cancer-virtual-meeting/ 2023-06-14T16:19:02+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-favourable-aware-1-safety-update/ 2023-06-14T16:19:13+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-aware-1-data-presented-at-the-34th-annual-meeting-of-the-society-for-immunotherapy-of-cancer/ 2023-06-14T16:19:35+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-preliminary-aware-1-trial-data-demonstrating-viral-replication-and-promotion-of-inflammation-following-systemic-administration-of-pelareorep-when-combined-with-tecentri/ 2023-06-14T16:19:58+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-first-patient-treated-in-companys-aware-1-window-of-opportunity-study-of-pelareorep-in-breast-cancer/ 2023-06-14T16:20:20+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechr-announces-spanish-regulatory-approval-of-aware-1-window-of-opportunity-study-in-breast-cancer/ 2023-06-14T16:20:51+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-collaborates-with-solti-to-conduct-a-window-of-opportunity-study-in-breast-cancer-with-pelareorep/ 2023-06-14T16:21:02+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-a-master-clinical-supply-agreement-of-an-anti-pd-l1-checkpoint-inhibitor-for-use-in-the-companys-clinical-program/ 2023-06-14T16:21:11+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-3/ 2023-06-15T13:23:45+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-first-quarter-2023-financial-results-and-operational-highlights/ 2023-06-15T13:25:06+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-upcoming-oral-presentation-on-randomized-bracelet-1-trial-in-hr-her2-metastatic-breast-cancer-at-the-asco-annual-meeting/ 2023-06-15T13:26:01+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-a-panel-presentation-at-canaccord-genuitys-horizons-in-oncology-virtual-conference/ 2023-06-15T13:27:53+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and-recent-operational-highlights-2/ 2023-06-15T13:28:35+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-filing-and-mailing-of-the-management-information-circular-in-connection-with-the-annual-general-meeting-of-shareholders/ 2023-06-15T13:29:58+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-a-panel-presentation-at-cantor-fitzgeralds-the-future-of-oncology-virtual-symposium/ 2023-06-15T13:31:12+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-fourth-quarter-and-full-year-2022-financial-results-and-operational-highlights/ 2023-06-15T13:31:58+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-2/ 2023-06-15T13:34:36+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-us15-million-bought-deal-offering-of-units/ 2023-08-07T11:07:02+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-a-fireside-chat-at-canaccord-genuitys-43rd-annual-growth-conference/ 2023-08-07T11:17:39+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-second-quarter-financial-results-and-recent-operational-highlights-2/ 2023-08-07T11:19:52+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-second-quarter-2023-financial-results-and-operational-highlights/ 2023-08-16T14:45:56+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-successfully-raises-us15-million-to-advance-breast-and-pancreatic-cancer-clinical-programs/ 2023-08-16T14:47:07+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-a-fireside-chat-at-the-h-c-wainwright-25th-annual-global-investment-conference/ 2023-09-15T14:46:25+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-full-exercise-of-over-allotment-option-from-public-offering/ 2023-09-15T14:47:19+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-key-opinion-leader-webinar-on-data-from-the-randomized-bracelet-1-trial-in-hr-her2-metastatic-breast-cancer-being-presented-at-the-upcoming-asco-annual-meeting/ 2023-09-15T14:49:15+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-positive-randomized-phase-2-data-from-bracelet-1-metastatic-breast-cancer-trial-demonstrating-pelareorep-drives-≥50-improvements-in-orr-and-mpfs-in-an-asco-a/ 2023-09-15T14:49:20+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-updated-randomized-phase-2-data-from-bracelet-1-metastatic-breast-cancer-trial-that-show-pelareorep-driving-robust-increases-in-progression-free-survival-and-confirm/ 2023-09-15T14:49:29+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotechs-pelareorep-selected-for-inclusion-in-precision-promisesm-pivotal-phase-3-platform-trial/ 2023-09-15T14:50:06+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-fireside-chat-at-the-cantor-global-healthcare-conference/ 2023-09-20T14:14:48+00:00 https://ir.oncolyticsbiotech.com/press_releases/the-pancreatic-cancer-action-network-selects-oncolytics-biotech-inc-to-receive-5-million-therapeutic-accelerator-award-to-develop-leading-edge-treatments/ 2023-10-17T09:29:15+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-two-posters-on-the-pelareorep-based-goblet-study-at-esmo-2023/ 2023-10-17T09:29:36+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-third-quarter-financial-results-and-recent-operational-highlights-2/ 2023-10-20T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-achieves-success-criteria-for-efficacy-in-the-third-line-colorectal-cancer-cohort-of-the-goblet-study/ 2023-10-24T14:19:05+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-presents-positive-updated-pancreatic-cancer-data-from-goblet-phase-1-2-study-at-esmo/ 2023-10-24T14:19:08+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-third-quarter-2023-financial-results-and-operational-highlights/ 2023-11-03T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-announces-the-anal-cancer-cohort-of-the-goblet-phase-1-2-study-of-pelareorep-and-atezolizumab-has-met-the-success-criteria-for-efficacy/ 2023-11-09T20:11:24+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-provides-update-on-pancreatic-cancer-program-for-pelareorep/ 2023-11-09T20:11:29+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-recaps-2023-accomplishments-provides-outlook-for-2024/ 2024-01-04T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors/ 2024-01-09T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-initiates-enrollment-expansion-of-goblet-anal-cancer-cohort/ 2024-02-14T14:12:18+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-presentation-at-the-cancer-advocacy-group-of-louisianas-3rd-annual-neauxcancer-conference/ 2024-02-28T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-3/ 2024-03-04T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-files-amendment-to-initiate-new-pancreatic-cancer-goblet-cohort-supported-by-pancan/ 2024-03-06T08:26:42+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-fourth-quarter-and-full-year-2023-financial-results-and-operational-highlights/ 2024-03-07T16:01:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-and-solti-present-positive-translational-data-at-sabcs/ 2024-03-20T15:34:45+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-a-panel-presentation-at-canaccord-genuitys-horizons-in-oncology-virtual-conference-2/ 2024-04-02T15:04:15+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-advances-toward-registration-enabling-trial-for-pelareorep-in-breast-cancer-with-submission-of-type-c-meeting-request-to-fda-2/ 2024-04-11T14:16:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and-recent-operational-highlights-3/ 2024-05-02T09:20:46+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-upcoming-presentations-at-the-american-society-of-clinical-oncology-annual-meeting/ 2024-05-02T11:25:14+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-a-fireside-chat-at-the-2024-rbc-capital-markets-global-healthcare-conference/ 2024-05-08T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-first-quarter-2024-financial-results-and-operational-highlights/ 2024-05-09T16:01:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-4/ 2024-05-16T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-receives-regulatory-clearance-to-evaluate-pelareorep-in-combination-with-modified-folfirinox-an-anti-pd-l1-inhibitor-in-pancreatic-cancer/ 2024-05-31T16:52:10+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-preliminary-collaboration-with-gcar-for-inclusion-of-pelareorep-in-anticipated-pancreatic-cancer-trial/ 2024-05-31T16:52:22+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-asco-abstracts-highlight-pelareoreps-potential-in-pancreatic-cancer-and-immunotherapeutic-mechanism-of-action/ 2024-05-31T16:52:32+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-doses-first-patient-in-study-of-pelareorep-folfirinox-combination-therapy-in-pancreatic-cancer/ 2024-06-20T15:40:08+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-president-and-chief-executive-officer-dr-matt-coffey-to-take-medical-leave-of-absence/ 2024-06-24T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-productive-fda-type-c-meeting-on-its-metastatic-breast-cancer-program/ 2024-06-27T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-and-solti-present-further-positive-pelareorep-translational-data-at-sitc/ 2024-07-09T16:17:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-second-quarter-financial-results-and-recent-operational-highlights-3/ 2024-07-24T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-second-quarter-2024-financial-results-and-operational-highlights/ 2024-08-01T16:01:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-a-fireside-chat-at-canaccord-genuitys-44th-annual-growth-conference/ 2024-08-02T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-participate-in-fireside-chats-at-two-investment-conferences-in-september/ 2024-09-06T08:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-favorable-results-for-bracelet-1-breast-cancer-study-reinforcing-path-to-funding-of-a-registration-enabling-study/ 2024-09-19T07:52:12+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-key-progress-and-upcoming-studies-for-breast-and-pancreatic-cancer-treatments-prepares-for-fda-accelerated-approval-path/ 2024-10-04T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-third-quarter-financial-results-and-recent-operational-highlights-3/ 2024-11-11T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-third-quarter-2024-financial-results-and-operational-highlights/ 2024-11-12T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-completion-of-initial-safety-phase-enrollment-for-goblet-trials-new-pancreatic-cancer-cohort/ 2024-12-03T14:51:34+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-promising-pelareorep-data-in-pancreatic-and-anal-cancers-at-asco-gi-symposium/ 2024-12-18T15:44:47+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-highlights-2024-achievements-and-prepares-for-an-influential-2025-with-promising-breast-and-gi-cancer-data/ 2024-12-23T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/regulatory-approval-clears-path-for-oncolytics-biotech-to-advance-promising-pancreatic-cancer-treatment-following-a-review-of-safety-data/ 2025-01-15T10:42:11+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-compelling-new-efficacy-and-safety-data-in-anal-and-pancreatic-cancers-at-2025-asco-gi-symposium/ 2025-01-22T13:09:13+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-matt-coffey-ph-d-will-not-return-to-ceo-role-following-medical-leave-of-absence/ 2025-02-07T21:24:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-strengthens-its-pipeline-in-2025-with-key-pancreatic-and-anal-cancer-advances-in-addition-to-metastatic-breast-cancer/ 2025-02-18T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-advances-key-pancreatic-and-anal-cancer-trials-strengthening-pipeline-in-2025/ 2025-02-19T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-financial-results-and-recent-operational-highlights-4/ 2025-02-25T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-highlights-and-financial-results-for-q4-and-year-end-2024/ 2025-03-07T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-and-pelareorep-discussed-during-recent-h-c-wainwright-key-opinion-leader-event-on-oncolytic-immunotherapies-in-breast-and-pancreatic-cancers/ 2025-04-10T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-funds-pelareoreps-ongoing-clinical-development-with-a-share-purchase-agreement-in-partnership-with-alumni-capital/ 2025-04-10T18:09:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-conference-call-to-discuss-first-quarter-financial-results-and-recent-operational-highlights-4/ 2025-05-06T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-showcase-new-pancreatic-cancer-data-at-asco-highlighting-pelareoreps-tumor-fighting-mechanism-of-action/ 2025-05-06T14:42:13+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-first-quarter-financial-results-and-highlights-clinical-momentum/ 2025-05-14T16:01:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-new-clinical-trial-data-at-asco-showing-pelareoreps-unique-immune-activation-capabilities/ 2025-05-23T09:57:23+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-names-new-ceo-to-accelerate-momentum-in-immunotherapy-programs/ 2025-06-11T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-appoints-former-ambrx-executive-as-chief-business-officer-to-drive-business-development-strategy/ 2025-06-30T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-highlights-transformative-pelareorep-survival-data-in-multiple-tumors-and-commitment-to-registration-enabling-studies/ 2025-07-08T08:30:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-host-key-opinion-leader-discussion-focusing-on-pancreatic-and-gastrointestinal-cancers/ 2025-07-10T08:30:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-presents-aggregated-translational-data-providing-evidence-of-pelareoreps-effectiveness-across-multiple-tumor-types/ 2025-07-16T08:30:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-regains-compliance-with-nasdaq-trading-rules/ 2025-07-22T15:32:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/key-opinion-leader-event-highlights-pelareoreps-compelling-pancreatic-and-gastrointestinal-data-and-future-potential/ 2025-07-23T09:39:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-engage-fda-for-potential-registration-enabled-study-in-first-line-pancreatic-cancer-with-goal-to-launch-trial-activities-by-year-end/ 2025-07-29T08:30:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-upcoming-annual-general-meeting-and-second-quarter-financial-results/ 2025-08-05T08:30:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-voluntary-delisting-from-the-toronto-stock-exchange/ 2025-08-08T09:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-second-quarter-financial-results-and-details-clinical-program-plans-for-pelareorep/ 2025-08-08T09:05:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-voting-results-from-the-annual-general-meeting-of-shareholders-5/ 2025-08-11T16:55:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-upcoming-investor-conferences-in-september/ 2025-08-28T08:30:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-provides-updated-clinical-safety-data-for-pelareorep-including-across-multiple-gastrointestinal-tumors/ 2025-09-02T09:10:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-highlights-strong-efficacy-and-translational-data-in-metastatic-colorectal-cancer-will-advance-regulatory-pathway-discussions/ 2025-09-08T07:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-provides-update-on-goblet-study-progress-and-u-s-site-expansion/ 2025-09-16T13:11:46+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-update-for-potential-first-line-pancreatic-cancer-registration-study/ 2025-09-29T08:30:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-updated-anal-cancer-data-showing-objective-response-rate-more-than-double-the-current-standard-of-care/ 2025-10-28T14:25:58+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-files-circular-prospectus-for-special-meeting-of-shareholders-to-change-jurisdiction-of-incorporation-to-nevada/ 2025-10-28T14:29:23+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-establishes-gastrointestinal-tumor-scientific-advisory-board-to-advance-pelareorep-as-a-platform-immunotherapy/ 2025-11-04T08:56:17+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-aligns-with-fda-on-pivotal-study-design-for-pelareorep-in-first-line-pancreatic-cancer/ 2025-11-19T11:25:41+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-provides-update-on-special-meeting-of-shareholders/ 2025-11-20T17:38:51+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reschedules-special-meeting-of-shareholders-to-change-jurisdiction-of-incorporation-to-nevada/ 2025-12-11T08:22:17+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-promising-efficacy-and-translational-data-supporting-pelareorep-in-kras-mutant-metastatic-colorectal-cancer/ 2026-01-23T14:19:27+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-expands-its-gastrointestinal-tumor-scientific-advisory-board-with-the-addition-of-dr-eileen-oreilly-dr-neil-segal-and-dr-van-morris/ 2026-01-23T14:21:22+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-provides-update-on-intellectual-property-strategy-and-patent-filings/ 2026-01-23T14:22:39+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-outlines-strategic-rationale-for-proposal-to-change-jurisdiction-of-incorporation-to-nevada/ 2026-01-23T14:24:32+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-appoints-john-mcadory-as-evp-of-strategy-and-operations-and-yujun-wu-to-lead-biostatistics/ 2026-01-23T14:27:21+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-results-of-special-meeting-of-shareholders/ 2026-01-23T14:28:35+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-updated-clinical-data-from-goblet-cohort-4-demonstrating-activity-of-pelareorep-plus-atezolizumab-in-third-line-anal-cancer/ 2026-02-19T08:15:52+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-receives-fda-fast-track-designation-for-pelareorep-in-2l-kras-mutant-mss-metastatic-colorectal-cancer/ 2026-02-19T12:26:18+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-prioritize-registration-focused-programs-in-anal-and-colorectal-cancer/ 2026-02-24T14:43:41+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-launches-randomized-colorectal-cancer-study/ 2026-03-02T09:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-new-mechanistic-and-translational-data-supporting-pelareorep-as-an-immune-priming-backbone-at-aacr-2026/ 2026-03-19T09:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-completes-domicile-change-to-the-united-states/ 2026-04-01T09:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-type-c-fda-meeting-to-discuss-single-arm-registrational-pathway-for-pelareorep-in-anal-cancer/ 2026-04-06T09:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-aligns-with-fda-on-planned-pivotal-anal-cancer-study/ 2026-04-27T08:10:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-reports-durable-responses-in-second-line-ras-mutant-mss-colorectal-cancer/ 2026-05-04T09:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-to-present-data-at-asco-2026-reinforcing-pelareoreps-potential-across-gastrointestinal-tumors/ 2026-05-22T15:45:42+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-positive-initial-preclinical-findings-supporting-further-evaluation-of-pelareorep-in-combination-with-ras-targeted-approaches/ 2026-06-01T09:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-announces-appointment-of-steve-glover-to-board-of-directors-and-promotion-of-john-mcadory-to-chief-operating-officer/ 2026-06-02T09:00:00+00:00 https://ir.oncolyticsbiotech.com/press_releases/oncolytics-biotech-secures-new-u-s-patent-protecting-commercial-manufacturing-of-pelareorep-into-2044/ 2026-06-16T09:00:00+00:00